{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:03:00Z","timestamp":1790787780775,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012479","name":"General Research Fund of Shanghai Normal University","doi-asserted-by":"publisher","award":["GRF12101222"],"award-info":[{"award-number":["GRF12101222"]}],"id":[{"id":"10.13039\/501100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012479","name":"General Research Fund of Shanghai Normal University","doi-asserted-by":"publisher","award":["GRF12101519"],"award-info":[{"award-number":["GRF12101519"]}],"id":[{"id":"10.13039\/501100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012479","name":"General Research Fund of Shanghai Normal University","doi-asserted-by":"publisher","award":["GRF12100221"],"award-info":[{"award-number":["GRF12100221"]}],"id":[{"id":"10.13039\/501100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"University Grants Committee Research Grants Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC81803788"],"award-info":[{"award-number":["NSFC81803788"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Committee","doi-asserted-by":"publisher","award":["JCYJ20200109150719846"],"award-info":[{"award-number":["JCYJ20200109150719846"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.phymed.2025.157151","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T14:52:11Z","timestamp":1754751131000},"page":"157151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Parthenolide inhibits Hsp90\u03b1 ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma"],"prefix":"10.1016","volume":"146","author":[{"given":"Xiao-Qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7761-0955","authenticated-orcid":false,"given":"Xiao-Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4282-2494","authenticated-orcid":false,"given":"Amy Sze-Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Xuan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5141-2633","authenticated-orcid":false,"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson Man-Shan","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1979-6769","authenticated-orcid":false,"given":"Guang-Hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanbiao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Qiong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-9608","authenticated-orcid":false,"given":"Zhi-Ling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2025.157151_bib0002","series-title":"Final Assessment Report On Tanacetum parthenium (L.) Schulz Bip., Herba - Revision 1","year":"2020"},{"issue":"8","key":"10.1016\/j.phymed.2025.157151_bib0003","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamaoncol.2016.0509","article-title":"Clinical, molecular, and immune analysis of dabrafenib-trametinib combination treatment for BRAF inhibitor\u2013refractory metastatic melanoma: a phase 2 clinical trial","volume":"2","author":"Chen","year":"2016","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.phymed.2025.157151_bib0004","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ccell.2025.02.013","article-title":"Sex hormones, the anticancer immune response, and therapeutic opportunities","volume":"43","author":"Conforti","year":"2025","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.phymed.2025.157151_bib0005","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00262-020-02643-3","article-title":"Sex differences in the association between tumor growth and T cell response in a melanoma mouse model","volume":"69","author":"Dakup","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.phymed.2025.157151_bib0006","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1634\/theoncologist.2016-0456","article-title":"Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma","volume":"22","author":"Daud","year":"2017","journal-title":"Oncologist"},{"issue":"9919","key":"10.1016\/j.phymed.2025.157151_bib0007","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.phymed.2025.157151_bib0008","doi-asserted-by":"crossref","first-page":"9553","DOI":"10.1200\/JCO.2019.37.15_suppl.9553","article-title":"Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (HSP90) inhibitor XL888 in advanced BRAFV600 mutant melanoma","volume":"37","author":"Eroglu","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.phymed.2025.157151_bib0009","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41419-020-2440-1","article-title":"Activation of STAT3 is a key event in TLR4 signaling-mediated melanoma progression","volume":"11","author":"Fu","year":"2020","journal-title":"Cell Death Dis."},{"issue":"17\u201318","key":"10.1016\/j.phymed.2025.157151_bib39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.drudis.2013.05.005","article-title":"Parthenolide: from plant shoots to cancer roots","volume":"18","author":"Ghantous","year":"2013","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.phymed.2025.157151_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","article-title":"Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer","volume":"21","author":"Grivennikov","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.phymed.2025.157151_bib0011","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pharmthera.2013.11.011","article-title":"BRAF inhibitors in cancer therapy","volume":"142","author":"Hertzman Johansson","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phymed.2025.157151_bib0012","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ctrv.2012.10.001","article-title":"Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions","volume":"39","author":"Hong","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phymed.2025.157151_bib0013","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.2147\/OTT.S182721","article-title":"Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US food and drug administration-approved targeted therapy in advanced melanoma","volume":"11","author":"Kakadia","year":"2018","journal-title":"Onco Targets Ther."},{"issue":"3","key":"10.1016\/j.phymed.2025.157151_bib0014","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/fft2.44","article-title":"Guidelines for cell viability assays","volume":"1","author":"Kamiloglu","year":"2020","journal-title":"Food Front."},{"issue":"5","key":"10.1016\/j.phymed.2025.157151_bib0015","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/acs.jmedchem.9b00940","article-title":"Heat shock protein 90 inhibitors: an update on achievements, challenges, and future directions","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phymed.2025.157151_bib0016","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jep.2017.07.023","article-title":"Computational and experimental prediction of molecules involved in the anti-melanoma action of berberine","volume":"208","author":"Liu","year":"2017","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"10.1016\/j.phymed.2025.157151_bib0017","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bmcl.2015.11.005","article-title":"Calycosin inhibits oxidative stress-induced cardiomyocyte apoptosis via activating estrogen receptor-\u03b1\/\u03b2","volume":"26","author":"Liu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phymed.2025.157151_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.603472","article-title":"Honokiol inhibits melanoma growth by targeting keratin 18 in vitro and in vivo","volume":"8","author":"Liu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.phymed.2025.157151_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.153084","article-title":"MiR-let-7a\/f-CCR7 signaling is involved in the anti-metastatic effects of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos in melanoma","volume":"64","author":"Liu","year":"2019","journal-title":"Phytomedicine"},{"issue":"10","key":"10.1016\/j.phymed.2025.157151_bib0020","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.phymed.2025.157151_bib0021","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21037\/atm.2016.06.07","article-title":"Resistant mechanisms to BRAF inhibitors in melanoma","volume":"4","author":"Manzano","year":"2016","journal-title":"Ann. Transl. Med."},{"issue":"3","key":"10.1016\/j.phymed.2025.157151_bib0022","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/annonc\/mdm545","article-title":"HSP90 as a marker of progression in melanoma","volume":"19","author":"McCarthy","year":"2008","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.phymed.2025.157151_bib0023","doi-asserted-by":"crossref","first-page":"10547","DOI":"10.1002\/anie.202015422","article-title":"Selective inhibition of the Hsp90\u03b1 isoform","volume":"60","author":"Mishra","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"3","key":"10.1016\/j.phymed.2025.157151_bib0024","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/acs.jmedchem.0c01700","article-title":"The development of Hsp90\u03b2-selective inhibitors to overcome detriments associated with pan-Hsp90 inhibition","volume":"64","author":"Mishra","year":"2021","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.phymed.2025.157151_bib0025","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1093\/emboj\/17.16.4829","article-title":"ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo","volume":"17","author":"Panaretou","year":"1998","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.phymed.2025.157151_bib0026","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1021\/jm980403y","article-title":"Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin","volume":"42","author":"Roe","year":"1999","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.phymed.2025.157151_bib0027","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/exd.13862","article-title":"UV-B-activated B16 melanoma cells or HaCaT keratinocytes accelerate signaling pathways associated with melanogenesis via ANGPTL 2 induction, an activity antagonized by chrysanthemum extract","volume":"28","author":"Satou","year":"2019","journal-title":"Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.phymed.2025.157151_bib0028","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.radonc.2015.06.026","article-title":"Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence","volume":"117","author":"Schick","year":"2015","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.phymed.2025.157151_bib40","doi-asserted-by":"crossref","unstructured":"Sch\u00fchly, W., Khan, I., Fischer, N.H., 2001. The Ethnomedicinal Uses of Magnoliaceae from the Southeastern United States as Leads in Drug Discovery. Pharmaceutical Biology 39(sup1), 63-69.","DOI":"10.1076\/phbi.39.s1.63.0006"},{"key":"10.1016\/j.phymed.2025.157151_bib0029","series-title":"Studies in Natural Products Chemistry","first-page":"337","article-title":"Chapter 9 - parthenolide and parthenolide-like sesquiterpene lactones as multiple targets drugs: current knowledge and new developments","author":"Seca","year":"2017"},{"issue":"1","key":"10.1016\/j.phymed.2025.157151_bib0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phymed.2025.157151_bib0031","series-title":"Survival Rates for Melanoma Skin Cancer","year":"2025"},{"issue":"1","key":"10.1016\/j.phymed.2025.157151_bib0032","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-5793(04)00229-7","article-title":"Hsp90 isoforms: functions, expression and clinical importance","volume":"562","author":"Subbarao Sreedhar","year":"2004","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.phymed.2025.157151_bib0033","doi-asserted-by":"crossref","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2024","volume":"22","author":"Swetter","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.phymed.2025.157151_bib0034","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.phymed.2025.157151_bib0035","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/biom13091276","article-title":"Novel anti-melanoma compounds are efficacious in A375 cell line xenograft melanoma model in nude mice","volume":"13","author":"Velayutham","year":"2023","journal-title":"Biomolecules."},{"issue":"10","key":"10.1016\/j.phymed.2025.157151_bib0036","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phymed.2025.157151_bib0037","article-title":"Tanshinone I Inhibits oxidative stress-induced cardiomyocyte injury by modulating Nrf2 signaling","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.phymed.2025.157151_bib0038","doi-asserted-by":"crossref","first-page":"e9934","DOI":"10.1371\/journal.pone.0009934","article-title":"Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity","volume":"5","author":"Zhao","year":"2010","journal-title":"PLoS One"}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325007901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325007901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:06:48Z","timestamp":1772824008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711325007901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"alternative-id":["S0944711325007901"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2025.157151","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parthenolide inhibits Hsp90\u03b1 ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2025.157151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"157151"}}